Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Anaplastic lymphoma kinase Stories

2011-09-29 09:38:00

Recently approved drug for treatment of an adult cancer is the latest example of how St. Jude scientific discoveries are used to identify new therapies that benefit patients regardless of age MEMPHIS, Tenn., Sept. 29, 2011 /PRNewswire-USNewswire/ -- A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how...

2011-09-01 12:54:27

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC). Lung adenocarcinoma can display genetic mutations, including anaplastic lymphoma kinase (ALK) rearrangement and...

2011-08-10 18:08:19

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain (IL-2RÃŽ³). The results, which appeared in a recent Proceedings of the National Academy of Sciences, suggest news targets for lymphoma and...

2011-08-04 14:01:22

When developing babies are growth restricted in the womb, they are typically born with heads that are large relative to their bodies. The growing brain is protected at the expense of other, less critical organs. Now, researchers reporting in the August 5th issue of Cell, a Cell Press publication, unearth new molecular evidence that explains just how the brain is spared. In studies of rapidly growing fruit fly larvae, they've traced this developmental phenomenon to the activity of a gene...

2011-08-02 20:57:58

A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer (IASLC). Lung cancer patients with ALK rearrangement have been found to respond well to crizotinib, an ALK inhibitor currently in clinical trials. Fluorescence in situ...

2011-05-23 07:30:00

ABBOTT PARK, Ill., May 23, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it filed premarket approval applications to the U.S. Food and Drug Administration and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect abnormal gene rearrangements in non-small-cell lung cancer (NSCLC) tumors. The test is a combination product to be used with Pfizer's crizotinib, an oral first-in class anaplastic lymphoma kinase (ALK) inhibitor. The...

2011-03-03 07:25:13

(Ivanhoe Newswire) --  Lung cancer is considered the 6th most common cause of cancer deaths in the United States.  Overall, 10-15% of lung cancers occur in people who have never smoked a single cigarette in their life.  But thanks to an inexpensive and rapid testing method, scientists can now efficiently identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence. It's a new test...

2011-02-07 15:58:01

Children's Hospital of Philadelphia finds new neuroblastoma target After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity. "Our study implicates this protein as a promising treatment target for high-risk neuroblastoma," said...

2010-10-27 16:01:00

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the...

2010-06-15 00:59:03

CHOP oncology chief working to translate his lab's genetic findings into treatments Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge"”much of it based on efforts by Maris and his colleagues at The Children's Hospital of...